ProtectomiR

INTRODUCTION:

MiRNAs are small non-coding RNAs, recognized as endogenous physiological regulators of gene expression. MiRNAs play important roles in physiological process in several organs and tissues, e.g. in myocardial infarction. The role of miRNAs in cardiac pathologies suggests their therapeutic and diagnostic potential.

TECHNOLOGY (INVENTION) DESCRIPTION:

Several miRNA compounds (miR-139-5p, miR-125b*, let-7b, miR-487b) termed ProtectomiRs for therapeutic use for cytoprotection in ischemic diseases, e.g. ischemic cardiac diseases, such as acute myocardial infarction.

ADVANTAGES OVER EXISTING SOLUTIONS:

Advantages: - Novel therapeutic concept: cytoprotective miRNAs involved in endogenous adaptation against myocardial ischemia/reperfusion injury - Currently unmet medical need, no approved therapies are on the market for target indications, e.g. acute myocardial infarction - ProtectomiRs identified by unbiased omics approach - Method to identify further protectomiRs - Booming therapeutic field with positive investment environment

DEVELOPMENT STATUS (STAGE):

Early preclinical stage, limited in vivo proof-of-concept.

PUBLICATIONS:

- Varga et al.: MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs. Am J Physiol Heart Circ Physiol. 307: H216–H227, 2014. - Varga et al.: miR-125b is a protectomiR: A rising star for acute cardioprotection. J Mol Cell Cardiol. 2017 Dec 30;115:51-53. - Perrino et al.: Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research (2017) 113, 725–736.

IP PROTECTION STATUS:

WO_2013/057527, primary filing date: 2012. Patent granted in USA, pending in national phases in China, EU.

TECHNOLOGY / IP OWNERS :

Intellectual property owner: Pharmahungary 2000 Ltd., a member of the Pharmahungary Group.